ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in San Antonio, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near San Antonio, TX, USA:

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

San Antonio, Texas, United States and 263 other locations

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

San Antonio, Texas, United States and 61 other locations

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung ...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Pemetrexed/Carboplatin
Drug: Pemetrexed/Cisplatin

Phase 3

AstraZeneca
AstraZeneca

San Antonio, Texas, United States and 152 other locations

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Pumitamig
Drug: Pembrolizumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

San Antonio, Texas, United States and 278 other locations

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung C...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Carboplatin

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

San Antonio, Texas, United States and 184 other locations

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

San Antonio, Texas, United States and 236 other locations

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to pati...

Enrolling
Non Small Cell
NSCLC (Non-small Cell Lung Cancer)
Drug: EPI-326

Phase 1

EpiBiologics

San Antonio, Texas, United States and 6 other locations

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (K...

Active, not recruiting
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)

Phase 3

Amgen
Amgen

San Antonio, Texas, United States and 222 other locations

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

(sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypo...

Enrolling
Non-small Cell Lung Cancer
NSCLC
Drug: Paclitaxel
Drug: Carboplatin

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

San Antonio, Texas, United States and 215 other locations

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Domvanalimab
Drug: Durvalumab

Phase 3

AstraZeneca
AstraZeneca

Fort Sam Houston, Texas, United States and 225 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems